Lifeboat Foundation

Researchers from the Netherlands Institute for Neuroscience (NIN) and the Leiden University Medical Center (LUMC) have shown that treatment using gene therapy leads to a faster recovery after nerve damage. By combining a surgical repair procedure with gene therapy, the survival of nerve cells and regeneration of nerve fibers over a long distance was stimulated for the first time. The discovery, published in the journal Brain, is an important step towards the development of a new treatment for people with nerve damage.

During birth or following a traffic accident, nerves in the neck can be torn out of the spinal cord. As a result, these patients lose their arm function, and are unable to perform daily activities such as drinking a cup of coffee. Currently, surgical repair is the only available treatment for patients suffering this kind of nerve damage. “After surgery, nerve fibers have to bridge many centimeters before reaching the muscles and nerve cells from which new fibers need to regenerate are lost in large numbers. Most regenerating nerve fiber do not reach the muscles. The recovery of arm function is therefore disappointing and incomplete,” explains researcher Ruben Eggers of the NIN.

2019 will likely see gene drives used in the wild, a universal flu vaccine, further advance of brain-machine interfaces, and more.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

Here, in Part 2 of a series of blogs on Longevity & Vitality, I explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

In this blog I’ll cover two classes of emerging technologies:

Continue reading “Longevity & Vitality Part 2: A Renaissance of Drugs and Genomics” »

Would you try a fecal pill to treat your medical condition?

They’ve already yielded a new lead in the hunt for better diabetes…

Researchers have demonstrated for the first time how two molecular strategies can safeguard CRISPR gene-drive experiments in the lab, according to a study published today in eLife.

Over the past 100 hundred years, the average human lifespan has increased dramatically, thanks to exponential advancements in science and technology. While living to 80, 90, and even 100 is a possibility, humans have long been in search of the ultimate discovery – immortality.

In order to achieve immortality, scientists have identified four key issues that must be overcome. These include telomere shortening, chronological aging, oxidative stress, and glycation. If these could be drastically reduced or even eliminated, immortality may just be in our reach. However, there are some promising technologies that are prolonging the human lifespan right now, and could eventually lead us to immortality.

It is definitely a creepy a concept to think about, but studies have shown that regular blood transfusions sourced can extend the human lifespan by 10–20 years. Scientists have found that a protein called GDF11 is very common in the blood of young mice, and has been shown to increase skeletal muscle and increase heart strength. This protein has been deemed to have anti-aging properties, making it a promising technology in extending human lifespan.

Continue reading “How Close are We to Achieving Immortality?” »

Research at the University of Arkansas on membrane proteins could lead to better development and testing of drugs. Chemistry researchers studied a type of membrane protein that expels drugs from a cell, contributing to drug resistance. They found that the lipid composition of the cell membrane has an effect on the behavior of these proteins, which should be taken into account when testing drugs that target membrane proteins. Their results are available open-access in the journal ACS Central Science.

London scientists are seeking to create a “Trojan horse” version of the flu virus to target advanced prostate cancer. A team at Barts Cancer Institute has won £245,000 from Prostate Cancer UK to continue pioneering research into a disease that kills 11,500 men a year. Early trials on mice have shown that the flu virus can be re-engineered to kill prostate cancer cells that have “metastasised” and spread away from the main tumour.